EDDING GENOR (06998) saw its shares rise nearly 9% during late trading. At the time of writing, the stock was up 6.88%, trading at HK$2.95, with a turnover of HK$3.5091 million.

On February 7, EDDING GENOR announced that its ANGPTL3 siRNA drug candidate, EDP167, has successfully administered the first dose in a Phase II clinical trial. The trial is a multicenter, dose-exploration, open-label study targeting adult patients with homozygous familial hypercholesterolemia (HoFH). The primary endpoint is the change in LDL-C levels from baseline after 24 weeks of treatment, with evaluation of the primary endpoint expected to be completed by the fourth quarter of 2026.

It is noteworthy that on December 30, Edding Pharmaceutical completed a reverse takeover by merging with Genor Biopharma and listing on the stock exchange. This reverse takeover marks the official establishment of EDDING GENOR and represents a new phase in strategic integration and development. The Chinese stock abbreviation for Genor Biopharma-B has been changed from "Genor Biopharma" to "EDDING GENOR," effective from 9:00 a.m. on February 6, 2026.